Last checked at 2 Sep 2021 07:00
2 September 2021
Belluscura PLC
("Belluscura" or the "Company")
Notice of Results
LONDON, U.K. AND PLANO, TX, U.S. (2 September 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that its unaudited interim results for the six month period ended 30 June 2021 will be released on Monday, 6 September 2021.
For further information please contact:
Belluscura plc | www.belluscura.com |
Robert Rauker, Chief Executive Officer | via Walbrook PR |
Anthony Dyer, Chief Financial Officer |
|
|
|
SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 |
Neil Baldwin |
|
|
|
Dowgate Capital Limited (Broker) | Tel: +44 (0)20 3903 7715 |
James Serjeant / Nicholas Chambers |
|
|
|
Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com |
Paul McManus / Sam Allen | Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 |
About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.